Clinical Trials Logo

Prurigo clinical trials

View clinical trials related to Prurigo.

Filter by:

NCT ID: NCT06427122 Recruiting - Atopic Dermatitis Clinical Trials

Effect of EMD Protocol for Urge on Dermatology-specific Quality of Life

EMD-U vs CAU
Start date: March 11, 2024
Phase: N/A
Study type: Interventional

The primary objective of this open randomised controlled trial is to assess the add-on effect of EMD-U compared to CAU alone, in improving dermatology-specific quality of life in patients with atopic dermatitis or prurigo nodularis who suffer from severe scratching behaviour. The main study parameter is the difference in treatment effect between EMD-U and CAU at T2, measured with the Skindex-29 symptoms scale. There are five measurement points: T0, T1 after 4 weeks, T2 after 8 weeks, T3 after 12 weeks, and T4 after 6 months. Patients are randomly allocated to either the EMD-U or CAU condition.

NCT ID: NCT06424470 Not yet recruiting - Prurigo Nodularis Clinical Trials

Study on the Treatment of Prurigo Nodularis With Stapokibart Injection

Start date: July 30, 2024
Phase: Phase 3
Study type: Interventional

This study is a multicenter, randomized, double-blind, placebo-controlled phase III clinical study to evaluate the efficacy and safety of Stapokibart Injection in the treatment of subjects with prurigo nodularis, and observe pharmacokinetic characteristics, pharmacological effects, and immunogenicity.

NCT ID: NCT06366750 Recruiting - Prurigo Nodularis Clinical Trials

A Study of Barzolvolimab in Patients With Prurigo Nodularis

Start date: April 12, 2024
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the efficacy and safety of barzolvolimab in adults with prurigo nodularis.

NCT ID: NCT06293053 Recruiting - Prurigo Nodularis Clinical Trials

A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥6 Months to <18 Years of Age With Prurigo Nodularis

Start date: May 15, 2024
Phase: Phase 3
Study type: Interventional

This is a Phase 3, multicenter, open-label, pharmacokinetics (PK)/safety study. The study consists of 3 periods: - Screening period: 2 to 4 weeks. - Treatment period: 24 weeks. - Post-intervention follow-up period: 16 weeks. The study duration will be approximately 42 to 44 weeks for each participant (including screening, treatment, and follow-up periods). The total number of planned study visits for each participant will be 6.

NCT ID: NCT06213831 Recruiting - Prurigo Nodularis Clinical Trials

A Study to Evaluate the Safety and Tolerability of Maximal Use Ruxolitinib Cream

Start date: February 27, 2024
Phase: Phase 1
Study type: Interventional

This study is being conducted to determine the safety and tolerability of ruxolitinib 1.5% cream under maximal use conditions in participants with Prurigo Nodularis (PN).

NCT ID: NCT06201715 Not yet recruiting - Prurigo Nodularis Clinical Trials

Efficacy and Safety of Tofacitinib in Patients With Prurigo Nodularis

Start date: May 1, 2024
Phase: N/A
Study type: Interventional

The goal is to evaluate the efficacy and safety of tofacitinib in treating refractory prurigo nodularis.The main questions it aims to answer are 1. whether tofacitinib is effective in treating prurigo nodularis in the longpterm. 2. whether tofacitinib is safe in prurigo nodularis patients in the longpterm.

NCT ID: NCT06087627 Recruiting - Prurigo Nodularis Clinical Trials

A Non-interventional Study to Describe the Dupilumab Long-term Treatment, Safety and Patient Reported Outcomes in Chronic Nodular Prurigo (Prurigo Nodularis) in Clinical Routine

CLEAR PN
Start date: December 27, 2023
Phase:
Study type: Observational [Patient Registry]

Prurigo nodularis (PN) is a skin disease characterized by the presence of single to multiple symmetrically distributed, intensively itching nodules. The main symptom is uncontrollable itching leading to prolonged, repetitive, and uncontrollable rubbing, scratching which in turn causes injuries to the skin. In recent years, number of studies evaluating PN, the affected population and the disease burden has increased but PN remains still understudied. This non-interventional study is intended to describe the long-term effectiveness of dupilumab (Dupixent®) in participants aged 18 years or older and suffering from moderate-to-severe PN who receive dupilumab for PN treatment in a real-world setting in Germany according to the prescribing information (Summary of Product Characteristics [SmPC]). The decision to initiate dupilumab treatment is made by the treating physician and participant according to the participant's medical need and to the standard of best medical practice. This decision is made independently and before data inclusion in this non-interventional study.

NCT ID: NCT05991323 Recruiting - Prurigo Nodularis Clinical Trials

Real-World Effectiveness of Dupilumab in Patients With Prurigo Nodularis: An Observational Study

GLOBOSPIN
Start date: December 12, 2023
Phase:
Study type: Observational

This study is a prospective, multinational, observational investigation designed to elucidate the real-world effectiveness and treatment patterns of dupilumab therapy in adult patients diagnosed with prurigo nodularis (PN). The primary objective of this study is to comprehensively characterize the real-world usage of dupilumab for the management of PN. In addition to this, the study aims to achieve several secondary objectives, including a detailed assessment of the medical history, socio-demographic and disease characteristics of dupilumab-treated PN patients, as well as the evaluation of the long-term real-world effectiveness of dupilumab therapy for PN.

NCT ID: NCT05764161 Recruiting - Prurigo Nodularis Clinical Trials

A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Prurigo Nodularis (PN)

TRuE-PN2
Start date: June 12, 2023
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the safety and tolerability of Ruxolitinib cream in participants with Prurigo Nodularis (PN).

NCT ID: NCT05755438 Recruiting - Prurigo Clinical Trials

A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Participants With Prurigo Nodularis (PN)

TRuE-PN1
Start date: March 10, 2023
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the safety and tolerability of Ruxolitinib cream in participants with Prurigo Nodularis (PN).